Chemotherapy and radiotherapy in nasopharyngeal carcinoma: An update of the MAC-NPC meta-analysis

The Lancet Oncology

Volumn 16, Issue 6, 2015, Pages 645-655

  Blanchard, Pierre ^a,b   Lee, Anne ^c   Marguet, Sophie ^a   Leclercq, Julie ^a   Ng, Wai Tong ^c   Ma, Jun ^d   Chan, Anthony T C ^e   Huang, Pei Yu ^d   Benhamou, Ellen ^a,b   Zhu, Guopei ^f   Chua, Daniel T T ^g   Chen, Yong ^d   Mai, Hai Qiang ^d   Kwong, Dora L W ^h   Cheah, Shie Lee ⁱ   Moon, James ^j   Tung, Yuk ^k   Chi, Kwan Hwa ^l   Fountzilas, George ^m   Zhang, Li ^d   Hui, Edwin Pun ^e   Lu, Tai Xiang ^d   Bourhis, Jean ⁿ   Pignon, Jean Pierre ^a,b   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^g HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

^h QUEEN MARY HOSPITAL   (Hong Kong)

ⁱ DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^j SWOG STATISTICAL CENTER   (United States)

^k TUEN MUN HOSPITAL   (Hong Kong)

^l Memorial Hospital   (Taiwan)

^m ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

ⁿ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; EPIRUBICIN; OXALIPLATIN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; DRUG EFFICACY; DRUG TREATMENT FAILURE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; META ANALYSIS; NASOPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK REDUCTION; SENSITIVITY ANALYSIS; SURVIVAL RATE; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MULTIMODALITY CANCER THERAPY; NASOPHARYNGEAL NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME;

CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; NASOPHARYNGEAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84930272841     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70126-9     Document Type: Article

References (33)

1. Lee AWM, Lin JC, Ng WT Current management of nasopharyngeal cancer. Semin Radiat Oncol 2012, 22:233-244.
2. Al-sarraf BM, Leblanc M, Giri PS, et al. Chemoradiotherpy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup Study 0099. J Clin Oncol 1998, 16:1310-1317.
3. Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006, 64:47-56.
4. Stewart LA, Clarke MJ Practical methodology of meta-analyses (overviews) using updated individual patient data: Cochrane Working Group. Stat Med 1995, 14:2057-2079.
5. Schemper M, Smith TL A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996, 17:343-346.
6. Yusuf S, Peto R, Lewis J, Collins R, Sleight P Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985, 27:335-371.
7. Stewart LA, Parmar MKB Meta-analysis of the literature or of individual patient data: is there a difference?. Lancet 1993, 341:418-422.
8. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992, 339:1-15. Early Breast Cancer Trialists' Collaborative Group.
9. Higgins JPT, Thompson SG Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
10. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995, 311:899-909. Non-small Cell Lung Cancer Collaborative Group.
11. Fisher DJ, Copas A, Tierney JF, Parmar MKB A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. J Clin Epidemiol 2011, 64:949-967.
12. Chan AT, Teo PM, Leung TW, et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1995, 33:569-577.
13. Chua DT, Sham JS, Choy DD, et al. Preliminary report of the Asian-oceanian clinical oncology association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinom. Cancer 1998, 83:2270-2283.
14. Preliminary results of a rendomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression. Int J Radiat Oncol Biol Phys 1996, 35:463-469. International Nasopharynx Cancer Study Group: VUMCA I Trial.
15. Hareyama M, Sakata K, Shirato H, et al. A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer 2002, 94:2217-2223.
16. Chi K-H, Chang Y-C, Guo W-Y, et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2002, 52:1238-1244.
17. Chan AT, Leung S, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005, 97:536-539.
18. Kwong DL, Sham JS, Au GK, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 2004, 22:2643-2653.
19. Chen L, Hu C-S, Chen X-Z, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012, 13:163-171.
20. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005, 23:6730-6738.
21. Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2010, 102:1188-1198.
22. Lee AW, Tung SY, Chan AT, et al. A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Radiother Oncol 2011, 98:15-22.
23. Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009, 27:242-249.
24. Fountzilas G, Ciuleanu E, Bobos M, et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2012, 23:427-435.
25. Wu X, Huang PY, Peng P, et al. Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma. Ann Oncol 2013, 24:2131-2136.
26. Huang P-Y, Cao K-J, Guo X, et al. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Oral Oncol 2012, 48:1038-1044.
27. Chen Q-Y, Wen Y-F, Guo L, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst 2011, 103:1761-1770.
28. Chen Y, Sun Y, Liang S-B, et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. Cancer 2013, 119:2230-2238.
29. Chen Y, Liu M-Z, Liang S-B, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China. Int J Radiat Oncol Biol Phys 2008, 71:1356-1364.
30. Lee AWM, Tung SY, Ngan RKC, et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. Eur J Cancer 2011, 47:656-666.
31. Lee AW, Ngan RK, Tung SY, et al. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer 2015, 121:1328-1338.
32. National Comprehensive Cancer Network guidelines (accessed April 23, 2015). http://www.nccn.org/professionals/physician_gls/pdf.
33. Blanchard P, Bourhis J, Lacas B, et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol 2013, 31:2854-2860.